Prevalence and Clinical Correlates of Microalbuminuria in Patients with Essential Hypertension - A Tertiary Care Center Cross Sectional Study.
Albuminuria is predictor of target organ damage and worse cardiovascular outcomes. Microalbuminuria has been found in a large number of patients with essential hypertension. Aim of our study was to evaluate the frequency of microalbuminuria in essential hypertension and to study its correlation with severity of hypertension and target organ damage. This cross-sectional study was conducted at the outpatient clinic of General Medicine department of Pt. B D Sharma PGIMS, Rohtak. Hundred patients of essential hypertension (group A) in the age group of 18-65 years were included in the study. A control group (group B) consisting of hundred healthy normotensive, age and sex matched volunteers were also entered into the study. Arterial blood pressure was measured by digital sphygmomanometer after five minutes of rest; the values reported represented the average of three consecutive measurements taken over a 15-minute period. Urine albumin excretion (UAE) was estimated by an immunoturbidometry method. Microalbuminuria was defined as UAE between 30 and 300 mg/24 hours. Statistical analysis was performed by standard methods to measure rates and proportions; chi square test was used for analyzing the associations between the variables. In this study it was observed that prevalence of microalbuminuria in essential hypertension was 47%. Risk factors for microalbuminuria included higher age, SBP and MAP. Microalbuminuria was associated with dyslipidemia, deranged renal parameters and end organ damage in form of LVH, ischemic changes, hypertensive retinopathy and renal dysfunction. In conclusion, this study confirmed that increased urinary albumin excretion is associated with a worse pattern of cardiovascular risk factors and is a marker of concomitant cardiovascular damage in essential hypertension. Microalbuminuria can therefore be regarded as a useful, relatively inexpensive, integrated marker to help identify patients at higher cardiovascular risk for whom more aggressive preventive strategies and additional treatment measures may be advisable.